✦ LIBER ✦

Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis

✍ Scribed by Kowdley, Kris V.; Gordon, Stuart C.; Reddy, K. Rajender; Rossaro, Lorenzo; Bernstein, David E.; Lawitz, Eric; Shiffman, Mitchell L.; Schiff, Eugene; Ghalib, Reem; Ryan, Michael; Rustgi, Vinod; Chojkier, Mario; Herring, Robert; Di Bisceglie, Adrian M.; Pockros, Paul J.; Subramanian, G. Mani; An, Di; Svarovskaia, Evguenia; Hyland, Robert H.; Pang, Phillip S.; Symonds, William T.; McHutchison, John G.; Muir, Andrew J.; Pound, David; Fried, Michael W.

Book ID: 121867344
Publisher: Massachusetts Medical Society
Year: 2014
Tongue: English
Weight: 508 KB
Volume: 370
Category: Article
ISSN: 0096-6762
DOI: 10.1056/NEJMoa1402355

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

O56 SOFOSBUVIR/LEDIPASVIR WITH AND WITHO

O56 SOFOSBUVIR/LEDIPASVIR WITH AND WITHOUT RIBAVIRIN FOR 8 WEEKS COMPARED TO SOFOSBUVIR/LEDIPASVIR FOR 12 WEEKS IN TREATMENT-NAÏVE NON-CIRRHOTIC GENOTYPE-1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-3 STUDY

✍ Kowdley, K.V.; Stuart, G.C.; Reddy, R.K.; Rossaro, L.; Bernstein, D.E.; An, D.; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 172 KB

764 Sofosbuvir/Ledipasvir With and Witho

764 Sofosbuvir/Ledipasvir With and Without Ribavirin for 8 Weeks Compared to Sofosbuvir/Ledipasvir for 12 Weeks in Treatment-Naive Non-Cirrhotic Genotype-1 HCV-Infected Patients: The Phase 3 Ion-3 Study

✍ Kowdley, Kris V.; Gordon, Stuart C.; Reddy, K. Rajender; Rossaro, Lorenzo; Berns 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 166 KB

O164 ALL ORAL FIXED-DOSE COMBINATION SOF

O164 ALL ORAL FIXED-DOSE COMBINATION SOFOSBUVIR/LEDIPASVIR WITH OR WITHOUT RIBAVIRIN FOR 12 OR 24 WEEKS IN TREATMENT-NAIVE GENOTYPE 1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-1 STUDY

✍ Mangia, A.; Marcellin, P.; Kwo, P.; Foster, G.R.; Buti, M.; Bräu, N.; Muir, A.; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 170 KB

Tu2038 All Oral Fixed-dose Combination S

Tu2038 All Oral Fixed-dose Combination Sofosbuvir/Ledipasvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Naive Genotype 1 HCV-Infected Patients: The Phase 3 ION-1 Study

✍ Jacobson, Ira M.; Marcellin, Patrick; Mangia, Alessandra; Kwo, Paul Y.; Foster, 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 46 KB

O109 ALL ORAL FIXED-DOSE COMBINATION SOF

O109 ALL ORAL FIXED-DOSE COMBINATION SOFOSBUVIR/LEDIPASVIR WITH OR WITHOUT RIBAVIRIN FOR 12 OR 24 WEEKS IN TREATMENT-EXPERIENCED GENOTYPE 1 HCV-INFECTED PATIENTS: THE PHASE 3 ION-2 STUDY

✍ Afdhal, N.; Reddy, R.K.; Pockros, P.; Di Bisceglie, A.M.; Arora, S.; Yang, J.C.; 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 151 KB

14 ALL-ORAL SOFOSBUVIR-BASED 12-WEEK REG

14 ALL-ORAL SOFOSBUVIR-BASED 12-WEEK REGIMENS FOR THE TREATMENT OF CHRONIC HCV INFECTION: THE ELECTRON STUDY

✍ Gane, E.J.; Stedman, C.A.; Hyland, R.H.; Pang, P.S.; Ding, X.; Symonds, W.T.; Mc 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 77 KB